Almirall buys derma firm Aqua for $305m+
This article was originally published in Scrip
Spanish pharma group Almirall has agreed to acquire Aqua Pharmaceuticals, a privately owned prescription dermatology company based in the US. It will pay $305m up front, and up to $75m in additional payments contingent on certain regulatory and commercial milestones being met during 2014 and 2015. It will also pay $22.6m up front related to amortization of certain long-term tax assets.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.